Cybin Inc. currently maintains an average "Buy" rating from five research firms. TD Cowen recently increased its price target for the stock from $8.00 to $62.00 while reiterating a "buy" rating.
HC Wainwright analysts also raised their Q2 2027 earnings per share estimates for the company. These revisions signal growing confidence in the pre-revenue biotechnology firm’s clinical development pipeline.